Lung Cancer
AstraZeneca, Daiichi Sankyo's Enhertu Scores FDA Accelerated Approval in HER2-Mutant Lung Cancer
The agency approved the first targeted therapy for this subset of non-small cell lung cancer patients based on data from the DESTINY-Lung02 trial.Â
Novartis' Tabrecta Nets Full FDA Approval for NSCLC With METex14 Skipping Mutations
The drug received accelerated approval two years earlier, but now the FDA is granting full approval based on confirmatory evidence of activity.Â
The EGFR C797X mutation is the most common on-target resistance mechanism to EGFR TKIs, and drugmakers behind fourth-generation inhibitors are trying to tackle it.
Mount Sinai Using $500K Grant to Study KRAS-Mutant Lung Cancer Treatments
The grant will support a collaborative project with NYU to develop combination therapies based on Jazz Pharmaceuticals' pan-RAF inhibitor JZP815.
Based on CodeBreaK 100/101 master protocol trial data, the firm is moving ahead with its study of Lumakras with Keytruda that may allow it to better manage toxicities.